Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01378117 · ClinicalTrials.gov registry record · Phase 4
Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT01378117 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 90 participants.
The verdict
NCT01378117, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
The study is a multicenter, prospective, open-label, randomized pilot study to investigate the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients.
Interventions
- DRUG Sitagliptin
- DRUG glargine
- DRUG lispro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01378117
The ClinicalTrials.gov registry entry for NCT01378117 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sitagliptin is the first listed.
NCT01378117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01378117 about?
NCT01378117 is a clinical study titled "Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes". The study is a multicenter, prospective, open-label, randomized pilot study to investigate the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients.
What is the current status of trial NCT01378117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2011-08. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01378117?
The interventions under investigation include: Sitagliptin (DRUG), glargine (DRUG), lispro (DRUG).
Who is sponsoring clinical trial NCT01378117?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.